Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2012. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMRs) regarding the vesting of conditional share awards under the GlaxoSmithKline Share Value Plan (SVP).
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. The only financial data point disclosed is the closing middle market price of an Ordinary share of GlaxoSmithKline plc on February 17, 2012, which was £14.14.
Material Changes
The material event reported is the conclusion of the three-year vesting period for 2009 SVP awards, which ended on February 16, 2012. Consequently, share awards vested on February 17, 2012, for specific PDMRs.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or contingencies. It is strictly a regulatory disclosure of share award vesting in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Share Vesting: Conditional share awards made in 2009 vested on February 17, 2012.
- Beneficiaries: Mr. P. Thomson and Mrs. V. A. Whyte each received 1,730 vested shares.
- Share Price: The closing middle market price on the vesting date was £14.14.
- Notification Date: The Company and PDMRs were advised of these transactions on February 20, 2012.